Neogen Chemicals has fully utilized its ₹161 crore preferential issue funds. The company reported no deviation in fund deployment, with proceeds allocated to subsidiaries, working capital, and corporate purposes. The monitoring report confirms the successful deployment, with the company now focusing on project outcomes.
Detailed Coverage
Neogen Chemicals Deploys Entire ₹161 Crore Preferential Issue Funds
Neogen Chemicals has successfully deployed the complete ₹161 crore raised through its preferential issue, with no deviation reported from the original objectives. The funds have been fully utilized across investments in wholly-owned subsidiaries, working capital requirements, and general corporate purposes. Reader Takeaway: Funds fully deployed; focus shifts to operational outcomes. ## What just happened Neogen Chemicals has completed the utilization of its ₹161 crore preferential issue. A final monitoring agency report confirms that all allocated funds have been deployed as per the disclosed objects in the offer document. The monitoring account balance is now nil. ## Why this matters This filing provides crucial transparency for investors, assuring them that the capital raised has been used for its intended purposes. Successful deployment indicates progress on the company's strategic initiatives, including expansion projects like the Pakhanjan facility and strengthening its financial position. ## The backstory Previously, Neogen Chemicals had undertaken a preferential issue to raise ₹161 crore. The stated objectives included investment in its wholly-owned subsidiaries, meeting working capital needs, and general corporate purposes. The final monitoring report signifies the conclusion of the fund utilization phase. ## What changes now With the funds fully deployed and the monitoring mandate concluded, the company's focus will now shift to executing the projects and realizing the intended benefits. This includes operationalizing the Pakhanjan project and the acquisition of the salt business. ## Risks to watch A key watch point is the final execution of the Business Transfer Agreement (BTA) for the salt business between Neogen Ionics Limited (NIL) and Neogen Morita New Materials Limited (NML). While funds have been allocated, the complete transfer is still in process and expected in the coming months. ## Peer comparison Companies in the specialty chemicals sector often raise funds through various instruments for capacity expansion and strategic acquisitions. The transparent reporting of fund utilization by Neogen Chemicals aligns with best practices for investor confidence. ## Context metrics (time-bound) * **Total Issue Size:** ₹161 crore * **Objects:** Investment in Wholly Owned Subsidiaries (₹100 crore), Working Capital (₹21 crore), General Corporate Purposes (₹40 crore). * **Fund Utilization:** ₹161 crore utilized. * **Reporting Status:** Final Monitoring Agency Report. * **Verification:** Certified by statutory auditors M/s Chandabhoy & Jassoobhoy as of July 23, 2026, and reviewed by the Audit Committee on July 24, 2026. ## What to track next Investors should monitor the progress and operational performance of the Pakhanjan project and the salt business acquisition. Successful integration and scaling of these assets will be key to future growth and profitability.
